Celecoxib - NuBioPharma
Alternative Names: Celecoxib oral suspension - NuBioPharma; Nu-Celecoxib™; NuCelecoxibLatest Information Update: 28 Jul 2023
At a glance
- Originator NuBioPharma
- Class Antimigraines; Antineoplastics; Antipyretics; Antirheumatics; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Pyrazoles; Small molecules; Sulfonamides
- Mechanism of Action Cyclo-oxygenase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Juvenile rheumatoid arthritis
Highest Development Phases
- No development reported Juvenile rheumatoid arthritis
Most Recent Events
- 28 Jul 2023 No recent reports of development identified for clinical-Phase-Unknown development in Juvenile-rheumatoid-arthritis(In adolescents, In children) in USA (PO, Suspension)
- 06 Jul 2021 Celecoxib is still in clinical trials for Juvenile rheumatoid arthritis in USA (NuBioPharma website, July 2021).
- 06 Jul 2021 Chemical structure information added